Printer Friendly

Understand the Clinical and Strategic Challenges to the Commercialization of Anti-Angiogenic and Vascular Targeting Drugs.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c43855) has announced the addition of "Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology" to their offering.

With Avastin as its bright star, the therapeutic field of anti-angiogenic and vascular targeting drugs in oncology is becoming re-energized. While fragmentation of the oncology market is set to occur as treatment becomes based on tumor growth drivers rather than primary tumor site, the use of targeted therapies, such as anti-angiogenesis chemotherapy agents.

Scope of this report:

- In-depth competitive landscape assessment of the anti-angiogenesis market in oncology

- Thorough review of utilized targets in anti-angiogenic and vascular target drug development

- Thorough review of approved drugs

- Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls

- Research and analysis highlights

Companies with the ten highest numbers of clinical trials make up more than 40% of all research and development done in anti-angiogenesis and vascular targeting in oncology, but they just constitute 10% of the competitors in the field.

More than 100 anti-angiogenic drugs have been described with one or more targets. These 75 drug targets are a mixture of weaker and stronger targets in angiogenesis.

The prostate cancer market is reaching maturity, and major players' sales have been eroded by the launch of various LHRH agonist depot formulations, we identify that angiogenesis inhibitors will be the most promising for future treatment of prostate cancer.

Key reasons to read this report:

- Understand the clinical and strategic challenges to the commercialization of anti-angiogenic and vascular targeting drugs

- Assess opportunities and risks for the continued development of anti-angiogenic and vascular targeting agents in five major cancer indications.

- Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

- Some of the almost 100 drugs included in this analysis

2-methoxyestradiol, AMG-706, ATN-161, AZD-2171, bevacizumab, combretastatin A-4 prodrug, enzastaurin hydrochloride, everolimus, neovastat, PTK/ZK, sorafenib tosylate, squalamine, thalidomide, vitaxin, XL-999, ZD-6474, volociximab etc.

Key Chapters Covered:

- Executive Summary

- Cancer Highlights

- Competitive Landscape in Anti-Angiogenesis and Vascular Targeting in Oncology

- Approved Anti-Angiogenic Cancer Drugs: Performance

- Target Analysis in Anti-Angiogenesis and Vascular Targeting

- Anti-angiogenesis and Vascular Targeting Drugs in Development: By Major Indications

- Drug Index

- Company Index

For more information visit http://www.researchandmarkets.com/reports/c43855
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 20, 2006
Words:380
Previous Article:Putting the Energy Back into Sales Management.
Next Article:Spectra Logic Named One of Colorado's Fastest Growing Technology Companies in Deloitte's Colorado Technology Fast 50 Program.
Topics:


Related Articles
Compound inhibits vessel growth, cancer.
Distinguished Oncology Researcher, Dr. Robert Kerbel, Discusses the Therapeutic Potential of Pairing Vascular Disrupting Agents with Anti-Angiogenic...
OXiGENE's Vascular Disrupting Agents Paired with Anti-Angiogenic Compound, Avastin, Yield Significant Increases in Anti-Tumor Activity.
OXiGENE to Commence First Ever Oncology Clinical Trial Combining a Vascular Disrupting Compound, Combretastatin A4P, with an Anti-Angiogenic Agent,...
Locus Pharmaceuticals Submits IND on Cancer Drug Candidate; First IND Establishes Transition to Clinical Stage Company.
First Patient Enrolled in OXiGENE's Phase Ib Trial of its Lead Vascular Disrupting Agent, CA4P, in Combination with an Antiangiogenic Agent,...
View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date inside 'Triple Analysis: Non Small Cell...
New Research Offers an In-Depth Competitive Landscape Assessment of the Targeted Oncology Market Place.
Take a Look at Preclinical and Clinical Phase Compounds That Are Most Likely to Succeed in the Cancer Therapeutics Market and Become High-Revenue...
Sirtex Supports the First Pilot Study Evaluating SIR-Spheres(R) Microspheres in Combination with Bevacizumab and Chemotherapy as a First Line...

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters